133 related articles for article (PubMed ID: 32535096)
1. The potential DPP-4 inhibitors from Xiao-Ke-An improve the glucolipid metabolism via the activation of AKT/GSK-3β pathway.
Jiang S; Wu X; Wang Y; Zou J; Zhao X
Eur J Pharmacol; 2020 Sep; 882():173272. PubMed ID: 32535096
[TBL] [Abstract][Full Text] [Related]
2. Adenosine N1-Oxide Exerts Anti-inflammatory Effects through the PI3K/Akt/GSK-3β Signaling Pathway and Promotes Osteogenic and Adipocyte Differentiation.
Ohashi E; Kohno K; Arai N; Harashima A; Ariyasu T; Ushio S
Biol Pharm Bull; 2019; 42(6):968-976. PubMed ID: 31155593
[TBL] [Abstract][Full Text] [Related]
3. Spleen-kidney supplementing formula alleviates insulin resistance via regulating AKT/glycogen synthase kinase 3β pathway in rats with type 2 diabetic induced by high-fat diet.
Tian C; Wang Y; La X; Li J; Zhang B
J Tradit Chin Med; 2019 Apr; 39(2):199-206. PubMed ID: 32186042
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
Rufinatscha K; Radlinger B; Dobner J; Folie S; Bon C; Profanter E; Ress C; Salzmann K; Staudacher G; Tilg H; Kaser S
Biochem Biophys Res Commun; 2017 Apr; 485(2):366-371. PubMed ID: 28213130
[TBL] [Abstract][Full Text] [Related]
5. Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes.
Liu Z; Xu L; Xing M; Xu X; Wei J; Wang J; Kang W
Biomed Pharmacother; 2020 May; 125():109952. PubMed ID: 32036216
[TBL] [Abstract][Full Text] [Related]
6. DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys.
Zhang Y; Chen Y; Cheng J; Guo Z; Lu Y; Tian B
Biochem Biophys Res Commun; 2015 Jan; 456(1):139-44. PubMed ID: 25446112
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors.
Deacon CF
Peptides; 2020 Mar; 125():170196. PubMed ID: 31706956
[TBL] [Abstract][Full Text] [Related]
8. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
10. p-Synephrine exhibits anti-adipogenic activity by activating the Akt/GSK3β signaling pathway in 3T3-L1 adipocytes.
Guo LX; Chen G; Yin ZY; Zhang YH; Zheng XX
J Food Biochem; 2019 Nov; 43(11):e13033. PubMed ID: 31486092
[TBL] [Abstract][Full Text] [Related]
11. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
13. Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway.
Hao J; Chen C; Huang K; Huang J; Li J; Liu P; Huang H
Eur J Pharmacol; 2014 Dec; 745():152-65. PubMed ID: 25310908
[TBL] [Abstract][Full Text] [Related]
14. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes.
Nie Y; Ma RC; Chan JC; Xu H; Xu G
FASEB J; 2012 Jun; 26(6):2383-93. PubMed ID: 22366643
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Omar B; Ahrén B
Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
[TBL] [Abstract][Full Text] [Related]
17. Activation of AKT1/GSK-3β/β-Catenin-TRIM11/Survivin Pathway by Novel GSK-3β Inhibitor Promotes Neuron Cell Survival: Study in Differentiated SH-SY5Y Cells in OGD Model.
Darshit BS; Ramanathan M
Mol Neurobiol; 2016 Dec; 53(10):6716-6729. PubMed ID: 26660108
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
Al-Damry NT; Attia HA; Al-Rasheed NM; Al-Rasheed NM; Mohamad RA; Al-Amin MA; Dizmiri N; Atteya M
Biomed Pharmacother; 2018 Nov; 107():347-358. PubMed ID: 30099338
[TBL] [Abstract][Full Text] [Related]
19. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
20. Multiple antidiabetic effects of three α-glucosidase inhibitory peptides, PFP, YPL and YPG: Dipeptidyl peptidase-IV inhibition, suppression of lipid accumulation in differentiated 3T3-L1 adipocytes and scavenging activity on methylglyoxal.
Ibrahim MA; Serem JC; Bester MJ; Neitz AW; Gaspar ARM
Int J Biol Macromol; 2019 Feb; 122():104-114. PubMed ID: 30365987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
